triple antagonist glp-1 GLP-1-based therapies for type 2 diabetes: from single, dual and agonists to endogenous production and L-cell differentiation | Diabetology & Metabolic Syndrome Schematic illustration of monoagonists, dual

Its that simple Terms of Use | Privacy Policy | Contact Us 2026 Ledisa

Watch Now Agenda *Agenda subject to change 6:30 PM Guest Arrival and Cocktail Reception 7:00 PM Welcome Participants Tyler Watson Executive Vice President of Marketing, The Atlantic Susan Sweeney Executive Vice President of Obesity and Related Conditions, Amgen 7:05 PM The Defining Scale Shift in Obesity Therapeutics Summary The first wave of obesity medications proved that biology works and sparked extraordinary demand

Yes, clinical trials suggest that Mounjaro (tirzepatide) can lead to greater weight loss compared to other GLP-1 medications like semaglutide (Wegovy) or liraglutide (Saxenda), particularly due to its dual action on GLP-1 and GIP receptors.

Cost is another considerable aspect of feasibility for healthcare systems and providers

Its surface appearance depends on two structural layers beneath it: the dermal matrix of collagen and elastin produced by fibroblasts, and the subcutaneous fat layer that acts as a volumizing scaffold pressing outward against it